PE20151776A1 - Compuestos de heteroarilo y sus usos - Google Patents
Compuestos de heteroarilo y sus usosInfo
- Publication number
- PE20151776A1 PE20151776A1 PE2015002022A PE2015002022A PE20151776A1 PE 20151776 A1 PE20151776 A1 PE 20151776A1 PE 2015002022 A PE2015002022 A PE 2015002022A PE 2015002022 A PE2015002022 A PE 2015002022A PE 20151776 A1 PE20151776 A1 PE 20151776A1
- Authority
- PE
- Peru
- Prior art keywords
- diseases
- optionally substituted
- compounds
- bivalent
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002430 hydrocarbons Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 abstract 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000001960 triggered effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793113P | 2013-03-15 | 2013-03-15 | |
| EP14305361 | 2014-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151776A1 true PE20151776A1 (es) | 2015-12-11 |
Family
ID=50390019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002022A PE20151776A1 (es) | 2013-03-15 | 2014-03-14 | Compuestos de heteroarilo y sus usos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9663524B2 (enExample) |
| EP (1) | EP2968337B1 (enExample) |
| JP (1) | JP6576325B2 (enExample) |
| KR (1) | KR102219695B1 (enExample) |
| CN (2) | CN111793068A (enExample) |
| AU (1) | AU2014228746B2 (enExample) |
| BR (1) | BR112015022191A8 (enExample) |
| EA (1) | EA036160B1 (enExample) |
| MA (1) | MA38393B1 (enExample) |
| MX (1) | MX374558B (enExample) |
| PE (1) | PE20151776A1 (enExample) |
| SG (1) | SG11201507478VA (enExample) |
| WO (1) | WO2014144737A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| LT3495367T (lt) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| JP6576325B2 (ja) | 2013-03-15 | 2019-09-18 | セルジーン シーエーアール エルエルシー | ヘテロアリール化合物およびそれらの使用 |
| CA2907243C (en) | 2013-03-15 | 2021-12-28 | Celgene Avilomics Research, Inc. | Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| SMT201800379T1 (it) | 2013-10-18 | 2018-09-13 | Eisai R&D Man Co Ltd | Inibitori di fgfr4 della pirimidina |
| BR112016008276B1 (pt) | 2013-10-25 | 2021-03-02 | Novartis Ag | derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica |
| DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| US10287268B2 (en) | 2014-07-21 | 2019-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| DK3172213T3 (da) | 2014-07-21 | 2021-12-13 | Dana Farber Cancer Inst Inc | Makrocykliske kinasehæmmere og anvendelser deraf |
| WO2016023014A2 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
| WO2016054483A1 (en) | 2014-10-03 | 2016-04-07 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| SG11201706287PA (en) | 2015-02-20 | 2017-09-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2016134294A1 (en) * | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| CA2976766A1 (en) | 2015-03-25 | 2016-09-29 | Novartis Ag | Formylated n-heterocyclic derivatives as fgfr4 inhibitors |
| CN107660200B (zh) | 2015-04-14 | 2022-01-11 | 卫材R&D管理有限公司 | 结晶fgfr4抑制剂化合物和其用途 |
| EP3454898B1 (en) | 2016-05-10 | 2021-11-10 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| KR20180002053A (ko) * | 2016-06-28 | 2018-01-05 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
| AU2017291812B2 (en) | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
| WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
| US11229643B2 (en) | 2016-11-02 | 2022-01-25 | Novartis Ag | Combinations of FGFR4 inhibitors and bile acid sequestrants |
| US10968220B2 (en) * | 2016-12-19 | 2021-04-06 | Abbisko Therapeutics Co., Ltd. | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof |
| BR112019017741A2 (pt) | 2017-02-28 | 2020-04-07 | Dana Farber Cancer Inst Inc | usos de pirimidopirimidinonas como inibidores de sik |
| CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| US11174255B2 (en) * | 2017-05-15 | 2021-11-16 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019015593A1 (zh) * | 2017-07-19 | 2019-01-24 | 江苏奥赛康药业股份有限公司 | 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 |
| CN109384790B (zh) * | 2017-08-08 | 2022-05-10 | 药捷安康(南京)科技股份有限公司 | 成纤维细胞生长因子受体抑制剂及其用途 |
| CN109745325B (zh) * | 2017-11-08 | 2022-02-15 | 上海翰森生物医药科技有限公司 | Fgfr4抑制剂、其制备方法和用途 |
| CN110386921A (zh) * | 2018-04-23 | 2019-10-29 | 南京药捷安康生物科技有限公司 | 成纤维细胞生长因子受体抑制剂化合物 |
| ES3061844T3 (en) | 2018-05-04 | 2026-04-07 | Incyte Corp | Salts of an fgfr inhibitor |
| MX2020011718A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas. |
| CN111868058B (zh) * | 2018-05-25 | 2023-06-13 | 上海和誉生物医药科技有限公司 | 一种fgfr抑制剂、其制备方法和在药学上的应用 |
| CN110577524B (zh) * | 2018-06-07 | 2022-01-28 | 北京大学深圳研究生院 | 一种激酶选择性抑制剂 |
| CN111936493B (zh) * | 2018-06-19 | 2023-05-26 | 上海和誉生物医药科技有限公司 | 一种高选择性FGFRi抑制剂及其制备方法和应用 |
| US12351576B2 (en) | 2018-09-14 | 2025-07-08 | Abbisko Therapeutics Co., Ltd. | FGFR inhibitor, preparation method therefor and application thereof |
| US20230065740A1 (en) | 2018-12-28 | 2023-03-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| WO2020177067A1 (en) | 2019-03-05 | 2020-09-10 | Bioardis Llc | Aromatic derivatives, preparation methods, and medical uses thereof |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| JP7378488B2 (ja) * | 2019-03-08 | 2023-11-13 | ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド | Ｆｇｆｒ４キナーゼ阻害剤、その製造方法及び用途 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR102333854B1 (ko) | 2019-10-24 | 2021-12-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
| GB201915828D0 (en) * | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| WO2021108803A1 (en) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR102382613B1 (ko) * | 2020-01-15 | 2022-04-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3213379A1 (en) * | 2021-03-26 | 2022-09-29 | Weiqiang Zhan | Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation, and a use thereof |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| CN113527311B (zh) * | 2021-08-23 | 2022-05-06 | 中南大学湘雅医院 | Fgfr4抑制剂、组合物及其在药物制备中的用途 |
| WO2023039828A1 (en) * | 2021-09-17 | 2023-03-23 | Nutshell Biotech (Shanghai) Co., Ltd. | Fused ring compounds as inhibitors of fgfr4 tyrosine kinases |
| CN113912602B (zh) * | 2021-10-14 | 2023-05-05 | 温州医科大学 | 一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途 |
| WO2024199388A1 (zh) * | 2023-03-29 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为myt1抑制剂的化合物 |
| EP4509142A1 (en) | 2023-08-16 | 2025-02-19 | Ona Therapeutics S.L. | Fgfr4 as target in cancer treatment |
| CN120775123A (zh) * | 2025-09-12 | 2025-10-14 | 怀化市恒渝新材料有限公司 | 一种光引发剂制备方法、光引发剂及其应用 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| MX9702245A (es) * | 1994-11-14 | 1997-06-28 | Warner Lambert Co | Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina. |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| KR20000070751A (ko) | 1997-02-05 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘 |
| DE19802377A1 (de) | 1998-01-22 | 1999-08-19 | Max Planck Gesellschaft | Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs |
| EE200000706A (et) | 1998-05-26 | 2002-06-17 | Warner-Lambert Company | Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid |
| CN1150195C (zh) | 1998-10-23 | 2004-05-19 | 霍夫曼-拉罗奇有限公司 | 双环氮杂环 |
| KR20020027649A (ko) | 1999-09-15 | 2002-04-13 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 카이나제 억제제로서의 프테리딘온 |
| KR100523120B1 (ko) * | 1999-10-21 | 2005-10-20 | 에프. 호프만-라 로슈 아게 | Ｐ38 단백질 키나제 저해제로서 헤테로알킬아미노-치환된이환 질소 헤테로환 |
| PL357494A1 (en) | 1999-10-21 | 2004-07-26 | F.Hoffmann-La Roche Ag | Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| MY141144A (en) | 2000-03-02 | 2010-03-15 | Smithkline Beecham Corp | 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| JP2004519422A (ja) | 2000-08-04 | 2004-07-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン |
| US6518276B2 (en) | 2000-08-31 | 2003-02-11 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (II) |
| CN100358892C (zh) | 2000-08-31 | 2008-01-02 | 霍夫曼-拉罗奇有限公司 | 7-氧代吡啶并嘧啶 |
| US6506749B2 (en) | 2000-08-31 | 2003-01-14 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (I) |
| BR0113628A (pt) | 2000-08-31 | 2003-07-01 | Hoffmann La Roche | 7-oxo-piridopirimidinas como inibidores de uma proliferação celular |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| US7196090B2 (en) | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| AU2003250475A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
| US7084270B2 (en) | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| TW200413381A (en) * | 2002-11-04 | 2004-08-01 | Hoffmann La Roche | Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
| US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| AU2003297431A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
| WO2004063195A1 (en) | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| JP2006522756A (ja) | 2003-04-10 | 2006-10-05 | エフ．ホフマン−ラ ロシュ アーゲー | ピリミド化合物 |
| MXPA05011103A (es) | 2003-04-16 | 2005-12-12 | Hoffmann La Roche | Compuestos de quinazolina. |
| WO2005011597A2 (en) | 2003-07-29 | 2005-02-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP4758349B2 (ja) | 2003-10-08 | 2011-08-24 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| WO2005066211A2 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| WO2005072826A2 (en) | 2004-01-21 | 2005-08-11 | Emory University | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection |
| WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| BRPI0514750A (pt) | 2004-08-31 | 2008-06-24 | Hoffmann La Roche | derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase |
| JP2008510690A (ja) | 2004-08-31 | 2008-04-10 | エフ．ホフマン−ラ ロシュ アーゲー | ３−フェニル−ジヒドロピリミド［４，５−ｄ］ピリミジノンのアミド誘導体、これらの製造、及び医薬品としての使用 |
| MX2007002434A (es) | 2004-08-31 | 2007-05-04 | Astrazeneca Ab | Derivados de quinazolinona y su uso como inhibidores de b-raf. |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
| EP1828186A1 (en) | 2004-12-13 | 2007-09-05 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| EP1878727A4 (en) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| CA2610598A1 (en) | 2005-06-10 | 2006-12-21 | Irm Llc | Compounds that maintain pluripotency of embryonic stem cells |
| WO2006137421A1 (ja) | 2005-06-21 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | 局所投与剤 |
| ES2336832T3 (es) | 2005-07-22 | 2010-04-16 | Five Prime Therapeutics, Inc. | Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr. |
| WO2007014250A2 (en) | 2005-07-26 | 2007-02-01 | Vertex Pharmaceuticals Incorporated | Abl kinase inhibition |
| KR100832594B1 (ko) * | 2005-11-08 | 2008-05-27 | 한미약품 주식회사 | 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법 |
| US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
| WO2007071752A2 (en) | 2005-12-21 | 2007-06-28 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| EP1963273A2 (en) | 2005-12-22 | 2008-09-03 | Wyeth a Corporation of the State of Delaware | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitors |
| JP5241704B2 (ja) * | 2006-05-11 | 2013-07-17 | アイアールエム・リミテッド・ライアビリティ・カンパニー | プロテインキナーゼ阻害剤としての化合物および組成物 |
| MX2008014618A (es) | 2006-05-15 | 2008-11-28 | Irm Llc | Composiciones y metodos para inhibidores de cinasas del receptor fgf. |
| WO2008047307A1 (en) | 2006-10-16 | 2008-04-24 | Gpc Biotech Inc. | Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors |
| EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| WO2008150260A1 (en) | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
| WO2008051820A2 (en) | 2006-10-20 | 2008-05-02 | Swagelok Company | Dc arc start with universal input |
| WO2008055842A1 (en) | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| EP2114941B1 (en) | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| PT2102164E (pt) * | 2006-12-27 | 2011-01-21 | Sanofi Aventis | Derivados de isoquinolina e de isoquinolinona substituída com cicloalquilamina |
| JP5313919B2 (ja) * | 2006-12-27 | 2013-10-09 | サノフイ | 新規な置換イソキノリン及びイソキノリノン誘導体 |
| CA2689429C (en) | 2007-06-15 | 2012-08-21 | Banyu Pharmaceutical Co., Ltd. | Bicycloaniline derivatives |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| US8216783B2 (en) | 2008-04-14 | 2012-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| CN102015660A (zh) | 2008-04-23 | 2011-04-13 | 协和发酵麒麟株式会社 | 2-氨基喹唑啉衍生物 |
| JP5351254B2 (ja) | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
| US20100121052A1 (en) | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| KR101341876B1 (ko) * | 2008-09-05 | 2013-12-20 | 셀진 아빌로믹스 리서치, 인코포레이티드 | 비가역 인히비터 디자인을 위한 알고리즘 |
| US8575179B2 (en) | 2008-12-12 | 2013-11-05 | Msd K.K. | Dihydropyrazolopyrimidinone derivatives |
| CA2745970A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
| CA2748181C (en) | 2009-01-06 | 2019-07-16 | Nathanael S. Gray | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| US9556426B2 (en) * | 2009-09-16 | 2017-01-31 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| AR079257A1 (es) | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| US20120258940A1 (en) | 2009-12-18 | 2012-10-11 | Giordano Caponigro | Method for treating haematological cancers |
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| WO2012122383A2 (en) | 2011-03-09 | 2012-09-13 | Avila Therapeutics, Inc. | Pi3 kinase inhibitors and uses thereof |
| BR112013024717A2 (pt) | 2011-04-07 | 2017-08-08 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo |
| HUE048834T2 (hu) | 2011-05-17 | 2020-08-28 | Univ California | Kináz inhibitorok |
| CN102887895B (zh) | 2011-07-22 | 2016-08-24 | 山东轩竹医药科技有限公司 | 吡啶并嘧啶类mTOR抑制剂 |
| CA2854462A1 (en) | 2011-11-04 | 2013-05-10 | Afraxis Holdings, Inc. | Pak inhibitors for the treatment of fragile x syndrome |
| DK3366293T3 (da) | 2012-06-07 | 2020-06-15 | Deciphera Pharmaceuticals Llc | Dihydronaphthyridiner og relaterede forbindelser, der er nyttige som kinashæmmere til behandling af proliferative sygdomme |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| JP6576325B2 (ja) | 2013-03-15 | 2019-09-18 | セルジーン シーエーアール エルエルシー | ヘテロアリール化合物およびそれらの使用 |
| AU2014287209B2 (en) | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| EP3027654B1 (en) | 2013-07-30 | 2019-09-25 | Blueprint Medicines Corporation | Pik3c2g fusions |
| WO2015017533A1 (en) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Ntrk2 fusions |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| LT3057969T (lt) | 2013-10-17 | 2018-07-10 | Blueprint Medicines Corporation | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit |
| SMT201800379T1 (it) | 2013-10-18 | 2018-09-13 | Eisai R&D Man Co Ltd | Inibitori di fgfr4 della pirimidina |
| DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
-
2014
- 2014-03-14 JP JP2016503031A patent/JP6576325B2/ja not_active Expired - Fee Related
- 2014-03-14 CN CN202010661205.XA patent/CN111793068A/zh active Pending
- 2014-03-14 EA EA201591420A patent/EA036160B1/ru not_active IP Right Cessation
- 2014-03-14 MX MX2015011514A patent/MX374558B/es active IP Right Grant
- 2014-03-14 EP EP14763001.6A patent/EP2968337B1/en active Active
- 2014-03-14 KR KR1020157029048A patent/KR102219695B1/ko not_active Expired - Fee Related
- 2014-03-14 US US14/776,373 patent/US9663524B2/en active Active
- 2014-03-14 CN CN201480016170.7A patent/CN105307657B/zh not_active Expired - Fee Related
- 2014-03-14 WO PCT/US2014/029270 patent/WO2014144737A1/en not_active Ceased
- 2014-03-14 AU AU2014228746A patent/AU2014228746B2/en not_active Ceased
- 2014-03-14 SG SG11201507478VA patent/SG11201507478VA/en unknown
- 2014-03-14 PE PE2015002022A patent/PE20151776A1/es unknown
- 2014-03-14 MA MA38393A patent/MA38393B1/fr unknown
- 2014-03-14 BR BR112015022191A patent/BR112015022191A8/pt active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| EP2968337A1 (en) | 2016-01-20 |
| EA201591420A1 (ru) | 2016-02-29 |
| CN105307657B (zh) | 2020-07-10 |
| CN105307657A (zh) | 2016-02-03 |
| AU2014228746A1 (en) | 2015-09-10 |
| EA036160B1 (ru) | 2020-10-08 |
| WO2014144737A1 (en) | 2014-09-18 |
| BR112015022191A2 (pt) | 2017-10-10 |
| US20160046634A1 (en) | 2016-02-18 |
| AU2014228746B2 (en) | 2018-08-30 |
| EP2968337A4 (en) | 2016-10-19 |
| US9663524B2 (en) | 2017-05-30 |
| KR20150131237A (ko) | 2015-11-24 |
| MX374558B (es) | 2025-03-06 |
| JP6576325B2 (ja) | 2019-09-18 |
| KR102219695B1 (ko) | 2021-02-25 |
| MA38393B1 (fr) | 2018-11-30 |
| BR112015022191A8 (pt) | 2018-01-23 |
| MA38393A3 (fr) | 2018-05-31 |
| JP2016519673A (ja) | 2016-07-07 |
| SG11201507478VA (en) | 2015-10-29 |
| EP2968337B1 (en) | 2021-07-21 |
| MX2015011514A (es) | 2016-08-11 |
| CN111793068A (zh) | 2020-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000072A (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina | |
| DOP2017000015A (es) | Compuestos de heteroarilo y sus usos | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| AR106763A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
| EA201100580A1 (ru) | Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
| DOP2019000030A (es) | Inhibidores de cdk2/4/6 | |
| CO7180199A2 (es) | Imidazotriazincarbonitrilos útiles como inhibidores de cinasa | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| EA201690098A1 (ru) | Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| CU24351B1 (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| UY31711A (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización | |
| AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
| PE20140927A1 (es) | Compuestos heterociclicos como inhibidores de cinasas | |
| MX2016004933A (es) | Inhibidores de pirimidina del fgfr4. | |
| MX2013008868A (es) | Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa. | |
| EA201390199A1 (ru) | 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение | |
| CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
| NI201200192A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica. | |
| MX374558B (es) | Compuestos de heteroarilo y sus usos. | |
| CO2019012571A2 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| EA201071224A1 (ru) | Ингибиторы limk2, композиции, содержащие их, и способы их применения | |
| TW201613938A (en) | Selective inhibitors for protein kinases, a pharmaceutical composition and an use thereof |